JP Stock MarketDetailed Quotes

4565 Nxera Pharma

Watchlist
  • 1491
  • +3+0.20%
20min DelayMarket Closed Aug 9 15:00 JST
134.05BMarket Cap-17102P/E (Static)

Nxera Pharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Nxera Pharma Earnings Date

Currency: JPY

Period

Q2 FY2024 Earnings

Aug 9, 2024

Revenue(YoY)

8.11B

+574.06%
EPS(YoY)

-15.86

-97.51%
Analyst Rating

Buy

Jul 17, 2024

Nxera Pharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 1 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: JPY

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 14.589B--
--2024/Q3-- / 16.600B--
Aug 9, 20242024/Q28.109B / 8.500B--
May 9, 20242024/Q14.611B / 11.300B--
Feb 13, 20242023/Q47.292B / 13.254B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 14.589B--
--2024/Q3-- / 16.600B--
Aug 9, 20242024/Q28.109B / 8.500B--
May 9, 20242024/Q14.611B / 11.300B--
Feb 13, 20242023/Q47.292B / 13.254B--

Unlock Free Earnings Estimates

Nxera Pharma Earnings Reports

  • Nxera Pharma: Confirmatory letter.

    Aug 9 03:02 ET

  • Nxera Pharma: Interim report - 35th period (01/01/2024 - 12/31/2024)

    Aug 9 03:01 ET

  • Nxera Pharma: Business highlights and consolidated performance for the second quarter (interim period) of December 2024 (January-June).

    Aug 9 02:30 ET

  • Nxera Pharma: December 2024, second quarter (interim period) financial results announcement [IFRS] (consolidated).

    Aug 9 02:30 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 17, 2024

    Buy

    • Strong Buy

      55.56%

    • Buy

      22.22%

    • Hold

      22.22%

    • Underperform

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    JP
    Overall
    Symbol
    Latest Price
    % Chg